Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Ph.D Jennifer Hammond, Heidi Leister-Tebbe, M.P.H Annie Gardner, M.S.P.T Paula Abreu, Ph.D Weihang Bao, Ph.D Wayne Wisemandle, Ph.D Marylynn Baniecki, B.Sc Victoria M Hendrick, Ph.D Bharat Damle, M.D Abraham Simón-Campos, M.D Rienk Pypstra, M.D James M Rusnak
New England Journal of Medicine, doi:10.1056/nejmoa2118542
BACKGROUND Nirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (M pro ) inhibitor with potent pan-human-coronavirus activity in vitro.
METHODS We conducted a phase 2-3 double-blind, randomized, controlled trial in which symptomatic, unvaccinated, nonhospitalized adults at high risk for progression to severe coronavirus disease 2019 (Covid-19) were assigned in a 1:1 ratio to receive either 300 mg of nirmatrelvir plus 100 mg of ritonavir (a pharmacokinetic enhancer) or placebo every 12 hours for 5 days. Covid-19-related hospitalization or death from any cause through day 28, viral load, and safety were evaluated.
RESULTS A total of 2246 patients underwent randomization; 1120 patients received nirmatrelvir plus ritonavir (nirmatrelvir group) and 1126 received placebo (placebo group). In the planned interim analysis of patients treated within 3 days after symptom onset (modified intention-to treat population, comprising 774 of the 1361 patients in the full analysis population), the incidence of Covid-19-related hospitalization or death by day 28 was lower in the nirmatrelvir group than in the placebo group by 6.32 percentage points (95% confidence interval [CI], −9.04 to −3.59; P<0.001; relative risk reduction, 89.1%); the incidence was 0.77% (3 of 389 patients) in the nirmatrelvir group, with 0 deaths, as compared with 7.01% (27 of 385 patients) in the placebo group, with 7 deaths. Efficacy was maintained in the final analysis involving the 1379 patients in the modified intention-to-treat population, with a difference of −5.81 percentage points (95% CI, −7.78 to −3.84; P<0.001; relative risk reduction, 88.9%). All 13 deaths occurred in the placebo group. The viral load was lower with nirmaltrelvir plus ritonavir than with placebo at day 5 of treatment, with an adjusted mean difference of −0.868 log 10 copies per milliliter when treatment was initiated within 3 days after the onset of symptoms. The incidence of adverse events that emerged during the treatment period was similar in the two groups (any adverse event, 22.6% with nirmatrelvir plus ritonavir vs. 23.9% with placebo; serious adverse events, 1.6% vs. 6.6%; and adverse events leading to discontinuation of the drugs or placebo, 2.1% vs. 4.2%). Dysgeusia (5.6% vs. 0.3%) and diarrhea (3.1% vs. 1.6%) occurred more frequently with nirmatrelvir plus ritonavir than with placebo.
CONCLUSIONS Treatment of symptomatic Covid-19 with nirmatrelvir plus ritonavir resulted in a risk of progression to severe Covid-19 that was 89% lower than the risk with placebo, without evident safety concerns. (Supported by Pfizer; ClinicalTrials.gov number, NCT04960202.
References
Anand, Ziebuhr, Wadhwani, Mesters, Hilgenfeld, Coronavirus main proteinase (3CL pro ) structure: basis for design of anti-SARS drugs, Science
Docherty, Harrison, Green, Features of 20 133 UK patients in hospital with Covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study, BMJ
Dougan, Nirula, Azizad, Bamlanivimab plus etesevimab in mild or moderate Covid-19, N Engl J Med
Gottlieb, Vaca, Paredes, Early remdesivir to prevent progression to severe Covid-19 in outpatients, N Engl J Med
Gupta, Gonzalez-Rojas, Juarez, Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab, N Engl J Med
Harvey, Carabelli, Jackson, SARS-CoV-2 variants, spike mutations and immune escape, Nat Rev Microbiol
Hilgenfeld, From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design, FEBS J
Kim, Garg, 'halloran, Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET), Clin Infect Dis
Lan, Demets, Discrete sequential boundaries for clinical trials, Biometrika
Mahase, Covid-19: what new variants are emerging and how are they being investigated?, BMJ
Merck, Merck and Ridgeback Biotherapeutics provide update on results from MOVe-OUT study of molnupiravir, an investigational oral antiviral medicine, in at risk adults with mild-to-moderate COV-ID-19
Merck, Merck and Ridgeback's investigational oral antiviral molnupiravir reduced the risk of hospitalization or death by approximately 50 percent compared to placebo for patients with mild or moderate COVID-19 in positive interim analysis of phase 3 study
Ncd-, RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19•2 million participants, Lancet
Ning, Liu, Li, Novel coronavirus (SARS-CoV-2) infection in a renal transplant recipient: case report, Am J Transplant
O'brien, Fleming, A multiple testing procedure for clinical trials, Biometrics
Owen, Allerton, Anderson, An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19, Science
Roth, Mensah, Johnson, Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study, J Am Coll Cardiol
Sevrioukova, Poulos, Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir, Proc Natl Acad Sci U S A
Shaughnessy, Re: emergency use authorization 091
Shaughnessy, Re: emergency use authorization 094
Shaughnessy, Re: emergency use authorization 100
Thakur, Dubey, Benitez, A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19, Sci Rep
Weinreich, Sivapalasingam, Norton, REGEN-COV antibody combination and outcomes in outpatients with Covid-19, N Engl J Med
Wu, Mcgoogan, Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention, JAMA
Yang, Xie, Xue, Design of wide-spectrum inhibitors targeting coronavirus main proteases, PLoS Biol
Zheng, Peng, Xu, Risk factors of critical & mortal COVID-19 cases: a systematic literature review and metaanalysis, J Infect
{ 'indexed': {'date-parts': [[2022, 2, 16]], 'date-time': '2022-02-16T22:41:36Z', 'timestamp': 1645051296577},
'reference-count': 21,
'publisher': 'Massachusetts Medical Society',
'license': [ { 'start': { 'date-parts': [[2022, 2, 16]],
'date-time': '2022-02-16T00:00:00Z',
'timestamp': 1644969600000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'http://www.nejmgroup.org/legal/terms-of-use.htm'}],
'funder': [{'DOI': '10.13039/100004319', 'name': 'Pfizer', 'doi-asserted-by': 'publisher'}],
'content-domain': {'domain': [], 'crossmark-restriction': False},
'short-container-title': ['N Engl J Med'],
'DOI': '10.1056/nejmoa2118542',
'type': 'journal-article',
'created': {'date-parts': [[2022, 2, 16]], 'date-time': '2022-02-16T22:00:58Z', 'timestamp': 1645048858000},
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': ['Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19'],
'prefix': '10.1056',
'author': [ { 'given': 'Jennifer',
'family': 'Hammond',
'sequence': 'first',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA (J.H., '
'H.L.-T.); Global Product Development (A.G.) and Early Clinical '
'Development (M.L.B.), Pfizer, Cambridge, MA; Global Product '
'Development, Pfizer, New York (P.A., W.B., B.D., R.P.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.W.); Medical and '
'Safety, Pfizer, Sandwich, United Kingdom (V.M.H.); Köhler and '
'Milstein Research, Mérida, Yucatan, Mexico (A.S.-C.); and Global '
'Product Development, Pfizer, Tampa, FL (J.M.R.).'}]},
{ 'given': 'Heidi',
'family': 'Leister-Tebbe',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA (J.H., '
'H.L.-T.); Global Product Development (A.G.) and Early Clinical '
'Development (M.L.B.), Pfizer, Cambridge, MA; Global Product '
'Development, Pfizer, New York (P.A., W.B., B.D., R.P.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.W.); Medical and '
'Safety, Pfizer, Sandwich, United Kingdom (V.M.H.); Köhler and '
'Milstein Research, Mérida, Yucatan, Mexico (A.S.-C.); and Global '
'Product Development, Pfizer, Tampa, FL (J.M.R.).'}]},
{ 'given': 'Annie',
'family': 'Gardner',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA (J.H., '
'H.L.-T.); Global Product Development (A.G.) and Early Clinical '
'Development (M.L.B.), Pfizer, Cambridge, MA; Global Product '
'Development, Pfizer, New York (P.A., W.B., B.D., R.P.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.W.); Medical and '
'Safety, Pfizer, Sandwich, United Kingdom (V.M.H.); Köhler and '
'Milstein Research, Mérida, Yucatan, Mexico (A.S.-C.); and Global '
'Product Development, Pfizer, Tampa, FL (J.M.R.).'}]},
{ 'given': 'Paula',
'family': 'Abreu',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA (J.H., '
'H.L.-T.); Global Product Development (A.G.) and Early Clinical '
'Development (M.L.B.), Pfizer, Cambridge, MA; Global Product '
'Development, Pfizer, New York (P.A., W.B., B.D., R.P.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.W.); Medical and '
'Safety, Pfizer, Sandwich, United Kingdom (V.M.H.); Köhler and '
'Milstein Research, Mérida, Yucatan, Mexico (A.S.-C.); and Global '
'Product Development, Pfizer, Tampa, FL (J.M.R.).'}]},
{ 'given': 'Weihang',
'family': 'Bao',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA (J.H., '
'H.L.-T.); Global Product Development (A.G.) and Early Clinical '
'Development (M.L.B.), Pfizer, Cambridge, MA; Global Product '
'Development, Pfizer, New York (P.A., W.B., B.D., R.P.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.W.); Medical and '
'Safety, Pfizer, Sandwich, United Kingdom (V.M.H.); Köhler and '
'Milstein Research, Mérida, Yucatan, Mexico (A.S.-C.); and Global '
'Product Development, Pfizer, Tampa, FL (J.M.R.).'}]},
{ 'given': 'Wayne',
'family': 'Wisemandle',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA (J.H., '
'H.L.-T.); Global Product Development (A.G.) and Early Clinical '
'Development (M.L.B.), Pfizer, Cambridge, MA; Global Product '
'Development, Pfizer, New York (P.A., W.B., B.D., R.P.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.W.); Medical and '
'Safety, Pfizer, Sandwich, United Kingdom (V.M.H.); Köhler and '
'Milstein Research, Mérida, Yucatan, Mexico (A.S.-C.); and Global '
'Product Development, Pfizer, Tampa, FL (J.M.R.).'}]},
{ 'given': 'MaryLynn',
'family': 'Baniecki',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA (J.H., '
'H.L.-T.); Global Product Development (A.G.) and Early Clinical '
'Development (M.L.B.), Pfizer, Cambridge, MA; Global Product '
'Development, Pfizer, New York (P.A., W.B., B.D., R.P.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.W.); Medical and '
'Safety, Pfizer, Sandwich, United Kingdom (V.M.H.); Köhler and '
'Milstein Research, Mérida, Yucatan, Mexico (A.S.-C.); and Global '
'Product Development, Pfizer, Tampa, FL (J.M.R.).'}]},
{ 'given': 'Victoria M.',
'family': 'Hendrick',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA (J.H., '
'H.L.-T.); Global Product Development (A.G.) and Early Clinical '
'Development (M.L.B.), Pfizer, Cambridge, MA; Global Product '
'Development, Pfizer, New York (P.A., W.B., B.D., R.P.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.W.); Medical and '
'Safety, Pfizer, Sandwich, United Kingdom (V.M.H.); Köhler and '
'Milstein Research, Mérida, Yucatan, Mexico (A.S.-C.); and Global '
'Product Development, Pfizer, Tampa, FL (J.M.R.).'}]},
{ 'given': 'Bharat',
'family': 'Damle',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA (J.H., '
'H.L.-T.); Global Product Development (A.G.) and Early Clinical '
'Development (M.L.B.), Pfizer, Cambridge, MA; Global Product '
'Development, Pfizer, New York (P.A., W.B., B.D., R.P.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.W.); Medical and '
'Safety, Pfizer, Sandwich, United Kingdom (V.M.H.); Köhler and '
'Milstein Research, Mérida, Yucatan, Mexico (A.S.-C.); and Global '
'Product Development, Pfizer, Tampa, FL (J.M.R.).'}]},
{ 'given': 'Abraham',
'family': 'Simón-Campos',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA (J.H., '
'H.L.-T.); Global Product Development (A.G.) and Early Clinical '
'Development (M.L.B.), Pfizer, Cambridge, MA; Global Product '
'Development, Pfizer, New York (P.A., W.B., B.D., R.P.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.W.); Medical and '
'Safety, Pfizer, Sandwich, United Kingdom (V.M.H.); Köhler and '
'Milstein Research, Mérida, Yucatan, Mexico (A.S.-C.); and Global '
'Product Development, Pfizer, Tampa, FL (J.M.R.).'}]},
{ 'given': 'Rienk',
'family': 'Pypstra',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA (J.H., '
'H.L.-T.); Global Product Development (A.G.) and Early Clinical '
'Development (M.L.B.), Pfizer, Cambridge, MA; Global Product '
'Development, Pfizer, New York (P.A., W.B., B.D., R.P.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.W.); Medical and '
'Safety, Pfizer, Sandwich, United Kingdom (V.M.H.); Köhler and '
'Milstein Research, Mérida, Yucatan, Mexico (A.S.-C.); and Global '
'Product Development, Pfizer, Tampa, FL (J.M.R.).'}]},
{ 'given': 'James M.',
'family': 'Rusnak',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA (J.H., '
'H.L.-T.); Global Product Development (A.G.) and Early Clinical '
'Development (M.L.B.), Pfizer, Cambridge, MA; Global Product '
'Development, Pfizer, New York (P.A., W.B., B.D., R.P.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.W.); Medical and '
'Safety, Pfizer, Sandwich, United Kingdom (V.M.H.); Köhler and '
'Milstein Research, Mérida, Yucatan, Mexico (A.S.-C.); and Global '
'Product Development, Pfizer, Tampa, FL (J.M.R.).'}]}],
'member': '150',
'published-online': {'date-parts': [[2022, 2, 16]]},
'container-title': ['New England Journal of Medicine'],
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'http://www.nejm.org/doi/pdf/10.1056/NEJMoa2118542',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2022, 2, 16]],
'date-time': '2022-02-16T22:00:59Z',
'timestamp': 1645048859000},
'score': 1,
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2022, 2, 16]]},
'references-count': 21,
'alternative-id': ['10.1056/NEJMoa2118542'],
'URL': 'http://dx.doi.org/10.1056/nejmoa2118542',
'relation': {},
'ISSN': ['0028-4793', '1533-4406'],
'issn-type': [{'value': '0028-4793', 'type': 'print'}, {'value': '1533-4406', 'type': 'electronic'}],
'subject': ['General Medicine'],
'published': {'date-parts': [[2022, 2, 16]]}}
